Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.35 |
| ▸ | TP53 | P04637 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.32 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.31 |
| ▸ | STAT6 | P42226 | 1/20 | 0.31 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.30 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26805652 | 0.88 | TLR7 (0.41) | PTK2TLR7STAT6 | |
| SCHEMBL26805638 | 0.85 | TP53 (0.36) | MAPTTP53LMNAPTK2TLR7 | |
| SCHEMBL26804233 | 0.80 | EPHX2 (0.34) | MAPTTP53LMNAPTK2STAT6 | |
| SCHEMBL24334795 | 0.78 | KCNH2 (0.36) | CYP11B1CYP11B2 | |
| SCHEMBL26805707 | 0.77 | TP53 (0.35) | MAPTTP53LMNAPTK2TLR7 | |
| SCHEMBL29564933 | 0.76 | P2RX7 (0.37) | PTK2CYP11B1CYP11B2 | |
| SCHEMBL24334963 | 0.76 | P2RX7 (0.37) | PTK2CYP11B1CYP11B2 | |
| SCHEMBL26804232 | 0.72 | P2RX7 (0.34) | PTK2CYP11B1CYP11B2 | |
| SCHEMBL24334965 | 0.69 | CYP11B1 (0.39) | MAPTTP53LMNACYP11B1CYP11B2 | |
| SCHEMBL29565367 | 0.68 | MTNR1A (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230382929-A1 | OLEFIN POLYMERIZATION CATALYSTS BEARING A 6-AMINO-N-ARYL AZAINDOLE LIGAND | DOW GLOBAL TECHNOLOGIES LLC (US) | 2023-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230382929-A1 | OLEFIN POLYMERIZATION CATALYSTS BEARING A 6-AMINO-N-ARYL AZAINDOLE LIGAND | AZI2, AOC2, CCNI | MAPT 1584/4885TP53 4103/4885LMNA 4280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.